Research · enforcement tracker
A public record of what regulators and marketplaces actually did about supplement marketing claims, and which standard each action maps to. Most entries are a claim a regulator, a platform or an advertising review body acted on. Every entry carries a date and a source. Nothing here is a prediction. Read it first, and fix your own wording before the next action lands in your category.
The record in numbers
Newest entry listed · 04 NOV 2026 · FDA warning letters post weekly, one to three weeks after issue.
What this tracker is
We do not invent standards. A phrase enters the standards only after a regulator, a marketplace or a court has acted on it. This page is that source record, kept in public so anyone can check the reasoning, cite the date, and see the date a rule changed for a claim they are still running.
Two kinds of entry. The dated events below are checked against their source and restated in one plain sentence each. The rest are pulled straight from three public records each week and listed exactly as published, with the date, the wording the body used, and a link to the action itself: FDA warning letters, FTC consumer-protection actions on health claims, and National Advertising Division and NARB decisions, which rule on advertising claims rather than statute.
The record, newest first
The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Good Life Discontinue Health Benefit and Personalization Claims for Compounded Tirzepatide+ Products.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: Following National Advertising Division Challenge, Davids Modifies and Discontinues Certain Claims for its Pulling Oil Oral Rinse.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/Adulterated.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/Adulterated.
FDA warning-letter database →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Qualified Saffron Claim Supported; Recommends Alice Mushrooms Discontinue Zen-X Health Claim.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: Acidified Foods/Emergency Permit Control/Adulterated/Misbranded.
FDA warning-letter database →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Hims & Hers Has Support for Combination Efficacy Message; Recommends Modification or Discontinuance of Other Claims.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: Unapproved New Drugs/Misbranded.
FDA warning-letter database →The National Advertising Division ruled on this advertiser’s claims. Decision as published: Following Reopened National Advertising Division Matter, Willow Health Services Voluntarily Discontinues Claims for Compounded Semaglutide Products.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: Unapproved New Drugs/Misbranded.
FDA warning-letter database →The Federal Trade Commission published this action. Headline as published: FTC Approves Final Order Against TruHeight for Deceptive and Unsubstantiated Advertising of Supplements for Kids and Teens.
FTC press release →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/New Drug/Misbranded.
FDA warning-letter database →The Federal Trade Commission published this action. Headline as published: FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims.
FTC press release →The FDA posted a warning letter to this company. Subject as published: Dietary Supplement/New Drug/Misbranded.
FDA warning-letter database →The Federal Trade Commission published this action. Headline as published: FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements for Children and Adults.
FTC press release →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Noom Modify or Discontinue “A Smaller Dose. A Smarter Start” Claim for Microdose GLP-1RX Program.
BBB National Programs, National Advertising Division →The National Advertising Review Board ruled on this advertiser’s claims. Decision as published: National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement Claims.
BBB National Programs, National Advertising Review Board →The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: New Drug/Misbranded.
FDA warning-letter database →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Nature’s Truth Modify or Discontinue Certain Magnesium Claims for Magnesium Glycinate Gummies.
BBB National Programs, National Advertising Division →Trade press reported that from 31 March 2026 Amazon began requiring detail-page content to align with the Supplement Facts panel, enforced automatically. Amazon’s published supplement policy now bars ingredient weight claims that do not match the panel (read 15 Oct 2026); the automatic enforcement is reported, not published.
NutraIngredients, 13 Mar 2026 →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Bayer Modify or Discontinue Certain One A Day Men’s Pre-Conception Health Complete Multivitamin Claims.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Refers Iron Rock NAD+ Dietary Supplement Claims to Regulatory Authorities.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Finds Certain CancerDetect® Claims Supported; Recommends Viome Modify or Discontinue Others.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Claims; Niagen to Appeal.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: National Advertising Division Recommends OLLY Modify “Calm & Relaxed” Claims for Kids Chillax Supplement.
BBB National Programs, National Advertising Division →The National Advertising Division ruled on this advertiser’s claims. Decision as published: In National Advertising Division Challenge, Midi Health Permanently Discontinues Challenged Claims for Menopause Care Services.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The National Advertising Division ruled on this advertiser’s claims. Decision as published: In National Advertising Division Challenge, Asutra Voluntarily Discontinues Claims for Magnesium Body Butter with Capsaicin.
BBB National Programs, National Advertising Division →The FDA posted a warning letter to this company. Subject as published: CGMP/Dietary Supplement/Adulterated/Misbranded.
FDA warning-letter database →The FDA posted a warning letter to this company. Subject as published: Unapproved New Drug/Misbranded.
FDA warning-letter database →Supplement, over-the-counter and functional-food marketers received a formal Notice of Penalty Offenses, which exposes unsubstantiated claims to civil penalties of $53,088 per violation under the statutory schedule.
Penalty figure: 16 CFR 1.98, 90 FR 5581 (17 Jan 2025); event: FTC Notice of Penalty Offenses distribution, Apr 2023 →A peer-reviewed analysis found 88% of tested melatonin gummy products were mislabelled, with measured doses running from 74% to 347% of the amount stated on the label.
Dates are the source’s own. Where a source gives only a month or a year, that is what we print.
What to do with it
01Check your copy
Read the entry, then read your listing. If an action names a claim family you are running, a regulator has already ruled against that wording somewhere. The claim rulings say what to write instead.
02Answer a letter
A warning letter starts a 15-business-day clock. The claims half of the reply is what we build: see warning-letter response.
03Cite it
Journalists, analysts and counsel are free to quote this record with attribution. The aggregate compliance data sits on the research page.
Cite usJournalists and researchers: this tracker is free to use. Credit “Claims Verified” and link here. Want to know how an entry was checked, or think we have one wrong? Email us directly and we will correct it.
audit@claimsverified.org →The brands in your category that fix this wording first can keep selling. FDA’s letters quote wording that was still live. Run one ASIN through the free check and see the severity counts on your own listing, ruled against the same 109 standards this record feeds.
The independent standard for supplement and telehealth claims. Our AI rules a brand’s public supplement claims against 109 published standards. Each failing line is rewritten to the rules. A licensed pharmacist signs every Claims Review Report.